Skip to main content
SpringerLink
Log in

Thyroid Cancer

  • Chapter
Challenging Cases in Endocrinology

Part of the book series: Contemporary Endocrinology ((COE))

  • 183 Accesses

Abstract

A 9-yr-old girl was referred to an endocrinologist in November 1995 after her pediatrician found a goiter. Her paternal grandmother and paternal uncle (who also had Down syndrome) both had thyroidectomies by age 20 yr for unknown reasons. The endocrinologist found the patient had high titers of antithyroid peroxidase antibodies, diagnosed Hashimoto’ s thyroiditis, and initiated thyroxine suppression therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA 1998; 48: 6–30.

    PubMed  CAS  Google Scholar 

  2. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993; 328: 553–559.

    Article  PubMed  CAS  Google Scholar 

  3. Moosa M, Mazzaferri EL. Occult thyroid carcinoma. Cancer J 1997; 10: 180–188.

    Google Scholar 

  4. Gharib H, Mazzaferri EL. Thyroxine suppressive therapy in patients with nodular thyroid disease. Ann Intern Med 1998; 128: 386–394.

    PubMed  CAS  Google Scholar 

  5. Csako G, Byrd D, Wesley RA, et al. Assessing the effects of thyroid suppression on benign solitary thyroid nodules. A model for using quantitative research synthesis. Medicine (Baltimore, MD) 2000; 79: 9–26.

    CAS  Google Scholar 

  6. Berghout A, Wiersinga WM, Drexhage HA, Smits NJ, Touber JL. Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre. Lancet 1990; 336: 193–197.

    Article  PubMed  CAS  Google Scholar 

  7. Kosary CL, Ries LAG, Miller BA, Hankey BF, Harras A, Edwards BK. SEER Cancer Statistic Review, 1973–1992: Tables and Graphs. Bethesda, MD: National Cancer Institute. NIH Pub. No. 96–2789, 1995.

    Google Scholar 

  8. Dottorini ME, Vignati A, Mazzucchelli L, Lomuscio G, Colombo L. Differentiated thyroid carcinoma in children and adolescents: A 37-year experience in 85 patients. J Nucl Med 1997; 38: 669–675.

    PubMed  CAS  Google Scholar 

  9. Samuel AM, Rajashekharrao B, Shah DH. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J Nucl Med 1998; 39: 1531–1536.

    PubMed  CAS  Google Scholar 

  10. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418–428.

    Article  PubMed  CAS  Google Scholar 

  11. Hung W. Well-differentiated thyroid carcinomas in children and adolescents: a review. Endocrinologist 1994; 4: 117–126.

    Article  Google Scholar 

  12. Mazzaferri EL. Thyroid carcinoma: papillary and follicular. In: Mazzaferri EL, Samaan N, eds. Endocrine Tumors. Blackwell Scientific, Cambridge, MA, 1993, pp. 278–333.

    Google Scholar 

  13. Harach HR, Williams ED. Childhood thyroid cancer in England and Wales. BrJ Cancer 1995; 72: 777–783.

    Article  CAS  Google Scholar 

  14. Schlumberger M, De Vathaire F, Travagli JP, et al. Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. J Clin Endocrinol Metab 1987; 65: 1088–1094.

    Article  PubMed  CAS  Google Scholar 

  15. LiVolsi VA. Unusual variants of papillary thyroid carcinoma. In: Mazzaferri EL, Kreisberg RA, Bar RS, eds. Advances in Endocrinology and Metabolism. Mosby-Year Book, St. Louis, MO, 1995, pp. 39–54.

    Google Scholar 

  16. Nikiforov Y, Gnepp DR. Pediatric thyroid cancer after the Chernobyl disaster: pathomorphologic study of 84 cases (1991–1992) from the Republic of Belarus. Cancer 1994; 74: 748–766.

    Article  PubMed  CAS  Google Scholar 

  17. Ain KB. Papillary thyroid carcinoma etiology, assessment, and therapy. Endocrinol Metabol Clin North Am 1995; 24: 711–760.

    CAS  Google Scholar 

  18. Yamashita H, Noguchi S, Murakami N, et al. Extracapsular invasion of lymph node metastasis-A good indicator of disease recurrence and poor prognosis in patients with thyroid microcarcinoma. Cancer 1999; 86: 842–849.

    Article  PubMed  CAS  Google Scholar 

  19. Noguchi M, Yamada H, Ohta N, et al. Regional lymph node metastases in well-differentiated thyroid carcinoma. Int Surg 1987; 72: 100–103.

    PubMed  CAS  Google Scholar 

  20. Sugino K, Ito K Jr, Ozaki O, Mimura T, Iwasaki H, Ito K. Papillary microcarcinoma of the thyroid. J Endocrinol Invest 1998; 21: 445–448.

    PubMed  CAS  Google Scholar 

  21. Yamashita H, Noguchi S, Murakami N, Kawamoto H, Watanabe S. Extracapsular invasion of lymph node metastasis is an indicator of distant metastasis and poor prognosis in patients with thyroid papillay carcinoma. Cancer 1997; 80: 2268–2272.

    Article  PubMed  CAS  Google Scholar 

  22. Mazzaferri EL, Young RL, Oertel JE, Kemmerer WT, Page CP. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltimore, MD) 1977; 56: 171–196.

    CAS  Google Scholar 

  23. Schlumberger M, Mancusi F, Baudin E, Pacini F. 131-I Therapy for elevated thyroglobulin levels. Thyroid 1997; 7: 273–276.

    Article  PubMed  CAS  Google Scholar 

  24. Kitamura Y, Shimizu K, Nagahama M, et al. Immediate causes of death in thyroid carcinoma: clinico-pathological analysis of 161 fatal cases. J Clin Endocrinol Metab 1999; 84: 4043–4049.

    Article  PubMed  CAS  Google Scholar 

  25. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998; 228: 320–328.

    Article  PubMed  CAS  Google Scholar 

  26. Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998; 83: 1121–1127.

    Article  PubMed  CAS  Google Scholar 

  27. Ringel M, Ladenson P, Levine MA. Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. J Clin Endocrinol Metab 1998; 83: 4435–4442.

    Article  PubMed  CAS  Google Scholar 

  28. Benua RS, Cicale NR, Sonenberg M, et. al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR 1962; 87: 171–178.

    CAS  Google Scholar 

  29. Bohuslavizki KH, Klutmann S, Brenner W, Mester J, Henze E, Clausen M. Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study. J Clin Oncol 1998; 16: 3542–3549.

    PubMed  CAS  Google Scholar 

  30. Edmonds CJ, Smith T. The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radio] 1986; 59: 45–51.

    Article  CAS  Google Scholar 

  31. Gunter HH, Schober O, Schwarzrock R, Hundeshagen H. Hematologic long-term modifications after radio-iodine therapy in carcinoma of the thyroid gland. II. Modifications of the bone marrow including leukemia. Strahlentherapie and Onkologie 1986; 163: 475–485.

    Google Scholar 

  32. Maxon H III, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metabol Clin North Am 1990; 19: 685–718.

    Google Scholar 

  33. Wong JB, Kaplan MM, Meyer KB, Pauker SG. Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. A decision analytic perspective. Endocrinol Metabol Clin North Am 1990; 19: 741–760.

    CAS  Google Scholar 

  34. Van Nostrand D, Neutze J, Atkins F. Side effects of “rational dose” iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med 1986; 27: 1519–1527.

    PubMed  Google Scholar 

  35. Brown AP, Greening WP, McCready VR, Shaw HJ, Harmer CL. Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience. Br J Radiol 1984; 57: 323–327.

    Article  PubMed  CAS  Google Scholar 

  36. Mazzaferri EL. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 1997; 7: 265–271.

    Article  PubMed  CAS  Google Scholar 

  37. Burmeister LA, Goumaz MO, Mariash CN, Oppenheimer JH. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 1992; 75: 344–350.

    Article  PubMed  CAS  Google Scholar 

  38. Bartalena L, Martino E, Pacchiarotti A, et al. Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients. J Clin Endocrinol Metab 1987; 64: 849–855.

    Article  PubMed  CAS  Google Scholar 

  39. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996; 81: 4318–4323.

    Article  PubMed  CAS  Google Scholar 

  40. Radetti G, Castellan C, Tatò L, Platter K, Gentili L, Adami S. Bone mineral density in children and adolescent females treated with high doses of L-thyroxine. Horm Res 1993; 39: 127–131.

    Article  PubMed  CAS  Google Scholar 

  41. Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1999; 8: 737–744.

    Article  Google Scholar 

  42. Maini CL, Sciuto R, Tofani A. TSH suppression by octreotide in differentiated thyroid carcinoma. Clin Endocrinol 1994; 40: 335–339.

    Article  CAS  Google Scholar 

  43. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993; 328: 553–559.

    Article  PubMed  CAS  Google Scholar 

  44. Hamming JF, Goslings BM, vanSteenis GJ, Claasen H, Hermans J, Velde JH. The value of fine-needle aspiration biopsy in patients with nodular thyroid disease divided into groups of suspicion of malignant neoplasms on clinical grounds. Arch Intern Med 1990; 150: 113–116.

    Article  PubMed  CAS  Google Scholar 

  45. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418–428.

    Article  PubMed  CAS  Google Scholar 

  46. Takasu N, Akamine H, Komiya I, Yamada T. Simple and reliable method for predicting the remission of Graves’ disease: Revised triiodothyronine-suppression test, indexed by serum thyroxine. J Endocrinol Invest 1995; 18: 288–294.

    PubMed  CAS  Google Scholar 

  47. Mazzaferri EL. Thyroid cancer and Graves’ disease. J Clin Endocrinol Metab 1990; 70: 826–829.

    Article  PubMed  CAS  Google Scholar 

  48. Mazzaferri EL. Thyroid cancer and Graves’ disease: the controversy ten years later. Endo Pract 2000; 6: 221–225.

    Article  CAS  Google Scholar 

  49. Vaiana R, Cappelli C, Perini P, et al. Hyperthyroidism and concurrent thyroid cancer. Tumori 1999; 85: 247–252.

    PubMed  CAS  Google Scholar 

  50. Kraimps JL, Bouin-Pineau MH, Marechaud R, Barbier J. (Basedow’s disease and thyroid nodules. A common association). Ann Chir 1998; 52: 449–451.

    PubMed  CAS  Google Scholar 

  51. Vini L, Hyer S, Pratt B, Harmer C. Good prognosis in thyroid cancer found incidentally at surgery for thyrotoxicosis. Postgrad Med J 1999; 75: 169–170.

    PubMed  CAS  Google Scholar 

  52. Chao TC, Lin JD, Jeng LB, Chen MF. Thyroid cancer with concurrent hyperthyroidism. Arch Surg 1999; 134: 130–134.

    Article  PubMed  CAS  Google Scholar 

  53. Oertli D, Harder F, Oberholzer M, Staub JJ. Hyperthyroidism and concurrent thyroid cancer-coincidence or association? Schweiz Med Wochenschr 1998; 128: 1910–1914.

    PubMed  CAS  Google Scholar 

  54. Belfiore A, Garofalo MR, Giuffrida D, et al. Increased aggressiveness of thyroid cancer in patients with Graves’ disease. J Clin Endocrinol Metab 1990; 70: 830–835.

    Article  PubMed  CAS  Google Scholar 

  55. Cantalamessa L, Baldini M, Orsatti A, Meroni L, Amodei V, Castagnone D. Thyroid nodules in Graves disease and the risk of thyroid carcinoma. Arch Intern Med 1999; 159: 1705–1708.

    Article  PubMed  CAS  Google Scholar 

  56. Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV. Malignant and benign neoplasm of the thyroid in patients treated for hyperthyroidism: a report of the Cooperative Thyrotoxicosis Therapy Follow-up Study. J Clin Endocrinol Metab 1974; 38: 976–998.

    Article  PubMed  CAS  Google Scholar 

  57. Caillou B, Troalen F, Baudin E, et al. Na+/I- symporter distribution in human thyroid tissues: an immunohistochemical study. J Clin Endocrinol Metab 1998; 83: 4102–4106.

    Article  PubMed  CAS  Google Scholar 

  58. Jhiang SM, Cho JY, Ryu K-Y, et al. An immunohistochemical study of Na+/I- symporter in human thyroid tissues and salivary gland tissues. Endocrinology 1998; 139: 4416–4419.

    Article  PubMed  CAS  Google Scholar 

  59. Ryu K-Y, Senokozlieff ME, Smanik PA, et al. Development of an RT-cPCR method to quantitate the expression levels of human Na+/I- symporter (hNIS). Thyroid 1999; 9: 405–409.

    Article  PubMed  CAS  Google Scholar 

  60. Filetti S, Belfiore A, Amir SM, et al. The role of thyroid-stimulating antibodies of Graves’ disease in differentiated thyroid cancer. N Engl J Med 1988; 318: 753–779.

    Article  PubMed  CAS  Google Scholar 

  61. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84: 3877–3885.

    Article  PubMed  CAS  Google Scholar 

  62. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996; 81: 4318–4323.

    Article  PubMed  CAS  Google Scholar 

  63. Tanaka K, Inoue H, Miki H, et al. Relationship between prognostic score and thyrotropin receptor (TSH-R) in papillary thyroid carcinoma: immunohistochemical detection of TSH-R. Br J Cancer 1997; 76: 594–599.

    Article  PubMed  CAS  Google Scholar 

  64. Gharib H, Mazzaferri EL. Thyroxine suppressive therapy in patients with nodular thyroid disease. Ann Intern Med 1998; 128: 386–394.

    PubMed  CAS  Google Scholar 

  65. Derwahl M, Broecker M, Kraiem Z. Thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors. J Clin Endocrinol Metab 1999; 84: 829–834.

    Article  PubMed  CAS  Google Scholar 

  66. Jhiang SM, Mazzaferri EL. The ret/PTC oncogene in papillary thyroid carcinoma. J Lab Clin Med 1994; 123: 331–337.

    PubMed  CAS  Google Scholar 

  67. Jhiang SM, Cho JY, Furminger TL, et al. Thyroid carcinomas in RET/PTC transgenic mice. Recent Results Cancer Res 1999; 154: 265–270.

    Article  Google Scholar 

  68. Russo D, Arturi F, Schlumberger M, et al. Activating mutations of the TSH receptor in differentiated thyroid carcinomas. Oncogene 1995; 11: 1907–1911.

    PubMed  CAS  Google Scholar 

  69. Russo D, Tumino S, Arturi F, et al. Detection of an activating mutation of the thyrotropin receptor in a case of an autonomously hyperfunctioning thyroid insular carcinoma. J Clin Endocrinol Metab 1997; 82: 735–738.

    Article  PubMed  CAS  Google Scholar 

  70. Spambalg D, Sharifi N, Elisei R, Gross JL, Medeiros-Neto G, Fagin JA. Structural studies of the thyrotropin receptor and Gsa in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation. J Clin Endocrinol Metab 1996; 81: 3898–3901.

    Article  PubMed  CAS  Google Scholar 

  71. Appetecchia M, Ducci M. Hyperfunctioning differentiated thyroid carcinoma. J Endocrinol Invest 1998; 21: 189–192.

    PubMed  CAS  Google Scholar 

  72. Le Pommelet C, Denizot A, Costagliola S, et al. Graves’ disease caused by metastatic thyroid cancer. Presse Med 1996; 25: 671–673.

    PubMed  Google Scholar 

  73. Katz SB, Garcia AJ, Niepomniszcze H. Development of Graves’ disease nine years after total thyroidectomy due to follicular carcinoma of the thyroid. Thyroid 1997; 7: 909–911.

    Article  PubMed  CAS  Google Scholar 

  74. Koong SS, Reynolds JC, Movius EG, et al. Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999; 84: 912–916.

    Article  PubMed  CAS  Google Scholar 

  75. Pons F, Carrio I, Estorch M, Ginjuame M, Pons J, Milian R. Lithium as an adjuvant of iodine-131 uptake when treating patients with well-differentiated thyroid carcinoma. Clin Nucl Med 1987; 8: 644–647.

    Article  Google Scholar 

  76. Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983; 309: 937–941.

    Article  PubMed  CAS  Google Scholar 

  77. Grünwald F, Menzel C, Bender H, et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 1998; 39: 903–1906.

    Google Scholar 

  78. Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988; 14: 1063–1075.

    Article  PubMed  CAS  Google Scholar 

  79. Samaan NA, Schultz PN, Haynie TP, Ordonez NG. Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab 1985; 60: 376–380.

    Article  PubMed  CAS  Google Scholar 

  80. Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 1988; 67: 501–558.

    Article  PubMed  CAS  Google Scholar 

  81. Schlumberger M, Challeton C, De Vathaire F, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996; 37: 598–605.

    PubMed  CAS  Google Scholar 

  82. Franceschi M, Kusic Z, Franceschi D, Lukinac L, Roncevic S. Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma. J Nucl Med 1996; 37: 446–451.

    PubMed  CAS  Google Scholar 

  83. Kitamura Y, Shimizu K, Nagahama M, et al. Immediate causes of death in thyroid carcinoma: clinico-pathological analysis of 161 fatal cases. J Clin Endocrinol Metab 1999; 84: 4043–4049.

    Article  PubMed  CAS  Google Scholar 

  84. Okayasu I, Fujiwara M, Hara Y, Tanaka Y, Rose NR. Association of chronic lymphocytic thyroiditis and thyroid papillary carcinoma-A study of surgical cases among Japanese, and white and African Americans. Cancer 1995; 76: 2312–2318.

    Article  PubMed  CAS  Google Scholar 

  85. Kashima K, Yokoyama S, Noguchi S, et al. Chronic thyroiditis as a favorable prognostic factor in papillary thyroid carcinoma. Thyroid 1998; 8: 197–202.

    Article  PubMed  CAS  Google Scholar 

  86. Schäffler A, Palitzsch KD, Seiffarth C, et al. Coexistent thyroiditis is associated with lower tumour stage in thyroid carcinoma. Eur J Clin Invest 1998; 28: 838–844.

    Article  PubMed  Google Scholar 

  87. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993; 328: 553–559.

    Article  PubMed  CAS  Google Scholar 

  88. Tielens ET, Sherman SI, Hruban RH, Ladenson PW. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study. Cancer 1994; 73: 424–431.

    Article  PubMed  CAS  Google Scholar 

  89. Brennan MD, Bergstralh EJ, van Heerden JA, McConahey WM. Follicular thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 1991; 66: 11–22.

    Article  PubMed  CAS  Google Scholar 

  90. Emerick GT, Duh Q-Y, Siperstein AE, Burrow GN, Clark OH. Diagnosis, treatment, and outcome of follicular thyroid carcinoma. Cancer 1993; 72: 3287–3295.

    Article  PubMed  CAS  Google Scholar 

  91. Mazzaferri EL. NCCN thyroid carcinoma practice guidelines. Oncology 1999; 13: 391–442.

    Google Scholar 

  92. Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994; 4: 49–54.

    Article  PubMed  CAS  Google Scholar 

  93. Muratet JP, Giraud P, Daver A, Minier JF, Gamelin E, Larra F. Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma. J Nucl Med 1997; 38: 1362–1368.

    PubMed  CAS  Google Scholar 

  94. Leger FA, Izembart M, Dagousset F, et al. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 1998; 25: 242–246.

    Article  PubMed  CAS  Google Scholar 

  95. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000; 85: 175–178.

    Article  PubMed  CAS  Google Scholar 

  96. Schlumberger MJ. Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest 1999; 22 (Suppl 11): 3–7.

    PubMed  CAS  Google Scholar 

  97. Schlumberger M, Mancusi F, Baudin E, Pacini F. 131-I Therapy for elevated thyroglobulin levels. Thyroid 1997; 7: 273–276.

    Article  PubMed  CAS  Google Scholar 

  98. Smanik PA, Liu Q, Furminger TL, et al. Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 1996; 226: 339–345.

    Article  PubMed  CAS  Google Scholar 

  99. Jhiang SM, Cho JY, Ryu K-Y, et al. An immunohistochemical study of Na+/I- symporter in human thyroid tissues and salivary gland tissues. Endocrinology 1998; 139: 4416–4419.

    Article  PubMed  CAS  Google Scholar 

  100. Schmutzler C, Köhrle J. Implications of the molecular characterization of the sodium-iodide symporter (NIS). Exp Clin Endocrinol Diabetes 1998; 106: S1 - S10.

    Article  PubMed  CAS  Google Scholar 

  101. Castro MR, Bergert ER, Beito TG, McIver B, Goellner JR, Morris JC. Development of monoclonal antibodies against the human sodium iodide symporter: immunohistochemical characterization of this protein in thyroid cells. J Clin Endocrinol Metab 1999; 84: 2957–2962.

    Article  PubMed  CAS  Google Scholar 

  102. Gruenwald F, Kaelicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999; 26: 1547–1552.

    Article  Google Scholar 

  103. Chung JK, So Y, Lee JS, et al. Value of FDG PET in papillary thyroid carcinoma with negative 1311 whole-body scan. J Nucl Med 1999; 40: 986–992.

    PubMed  CAS  Google Scholar 

  104. Wang W, Larson SM, Fazzari M, et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000; 85: 1107–1113.

    Article  PubMed  CAS  Google Scholar 

  105. Vassilopoulou-Sellin R, Schultz PN, Haynie TP. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Cancer 1996; 78: 493–501.

    Article  PubMed  CAS  Google Scholar 

  106. Schlumberger M, Challeton C, De Vathaire F, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996; 37: 598–605.

    PubMed  CAS  Google Scholar 

  107. Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998; 83: 1121–1127.

    Article  PubMed  CAS  Google Scholar 

  108. Spencer CA. Recoveries cannot be used to authenticate thyroglobulin (Tg) measurements when sera contain Tg autoantibodies. Clin Chem 1996; 42: 661–663.

    PubMed  CAS  Google Scholar 

  109. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84: 3877–3885.

    Article  PubMed  CAS  Google Scholar 

  110. Pacini F, Lari R, Mazzeo S, Grasso L, Taddei D, Pinchera A. Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin Endocrinol 1985; 23: 405–411.

    Article  CAS  Google Scholar 

  111. Muller-Gartner HW, Schneider C. Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer. Cancer 1988; 61: 976–981.

    Article  PubMed  CAS  Google Scholar 

  112. Ringel M, Ladenson P, Levine MA. Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. J Clin Endocrinol Metab 1998; 83: 4435–4442.

    Article  PubMed  CAS  Google Scholar 

  113. Ronga G, Fiorentino A, Fragasso G, Fringuelli FM, Todino V. Complementary role of whole body scan and serum thyroglobulin determination in the follow-up of differentiated thyroid carcinoma. Ital J Surg Sci 1986; 16: 11–15.

    PubMed  CAS  Google Scholar 

  114. Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, DeGroot Li. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994; 79: 98–105.

    Article  PubMed  CAS  Google Scholar 

  115. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyroglobulin assays. Clin Chem 1996; 42: 164–173.

    PubMed  CAS  Google Scholar 

  116. Schlumberger MJ. Medical progress—Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338: 297–306.

    Article  Google Scholar 

  117. Spencer CA, Wang CC. Thyroglobulin measurement—Techniques, clinical benefits, and pitfalls. Endocrinol Metabol Clin North Am 1995; 24: 841–863.

    CAS  Google Scholar 

  118. Schlumberger M, Mancusi F, Baudin E, Pacini F. 131-I Therapy for elevated thyroglobulin levels. Thyroid 1997; 7: 273–276.

    Article  PubMed  CAS  Google Scholar 

  119. Mazzaferri EL. Carcinoma of follicular epithelium: radioiodine and other treatment outcomes. In: Braverman LE, Utiger RD, eds. The Thyroid: A Fundamental and Clinical Text. Lippencott-Raven, Philadelphia, PA, 1996, pp. 922–945.

    Google Scholar 

  120. Brierley J, Maxon HR. Radioiodine and external radiation therapy. In: Fagin JA, ed. Thyroid Cancer. Kluwer Academic, Boston/Dordrecht London: 1998, pp. 285–317.

    Chapter  Google Scholar 

  121. Maxon HR, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer-a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992; 33: 1132–1136.

    PubMed  Google Scholar 

  122. Benua RS, Cicale NR, Sonenberg M, et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR 1962; 87: 171–178.

    CAS  Google Scholar 

  123. Rudaysky AZ. Freeman LM. Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone. J Clin Endocrinol Metab 1997; 82: 11–14.

    Article  Google Scholar 

  124. Schlumberger M, Tubiana M, De Vathaire F, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986; 63: 960967.

    Google Scholar 

  125. Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 1987; 28: 1888–1891.

    PubMed  CAS  Google Scholar 

  126. Casara D, Rubello D, Saladini G, et al. Different features of pulmonary metastases in differentiated thyroid cancer: Natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993; 34: 1626–1631.

    PubMed  CAS  Google Scholar 

  127. Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 1988; 29: 1790–1794.

    PubMed  CAS  Google Scholar 

  128. Pineda JD, Lee T, Ain K, Reynolds J, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995; 80: 1488–1492.

    Article  PubMed  CAS  Google Scholar 

  129. Beierwaltes WH, Nishiyama RH, Thompson NW, Copp JE, Kubo A. Survival time and “cure” in papillary and follicular thyroid carcinoma with distant metastases: statistics following University of Michigan therapy. J Nucl Med 1982; 23: 561–568.

    PubMed  CAS  Google Scholar 

  130. Brown AP, Greening WP, McCready VR, Shaw HJ, Harmer CL. Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience. Br J Radiol 1984; 57: 323–327.

    Article  PubMed  CAS  Google Scholar 

  131. Samuel AM, Rajashekharrao B, Shah DH. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J Nucl Med 1998; 39: 1531–1536.

    PubMed  CAS  Google Scholar 

  132. Sisson JC, Giordano TJ, Jamadar DA, et al. 131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. Cancer 1996; 78: 2184–2192.

    Article  PubMed  CAS  Google Scholar 

  133. Schlumberger M, Challeton C, De Vathaire F, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996; 37: 598–605.

    PubMed  CAS  Google Scholar 

  134. Giuffrida D, Fornito MC, Pellegriti G, Regalbuto C, Vigneri G. False positive 1311 total body scan due to bilateral polycystic renal disease. J Endocrinol Invest 1997; 20: 342–344.

    PubMed  CAS  Google Scholar 

  135. Greenler DP, Klein HA. The scope of false-positive iodine-131 images for thyroid carcinoma. Clin Nucl Med 1989; 14: 111–117.

    Article  PubMed  CAS  Google Scholar 

  136. Chung JK, Lee YJ, Jeong JM, et al. Clinical significance of hepatic visualization on iodine-131 whole-body scan in patients with thyroid carcinoma. J Nucl Med 1997; 38: 1191–1195.

    PubMed  CAS  Google Scholar 

  137. Mazzaferri EL. Thyroid carcinoma: papillary and follicular. In: Mazzaferri EL, Samaan N, eds. Endocrine Tumors. Blackwell Scientific, Cambridge,MA, 1993, pp. 278–333.

    Google Scholar 

  138. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985–1995. Cancer 1998; 83: 2638–2648.

    Article  PubMed  CAS  Google Scholar 

  139. Robbins J, Schneider AB. Radioiodine-induced thyroid cancer: studies in the aftermath of the accident at Chernobyl. Trends Endocrinol Metab 1998; 9: 87–94.

    Article  PubMed  CAS  Google Scholar 

  140. LiVolsi VA. Unusual variants of papillary thyroid carcinoma. In: Mazzaferri EL, Kreisberg RA, Bar RS, eds. Advances in Endocrinology and Metabolism. Mosby-Year Book, St. Louis, MO, 1995, pp. 39–54.

    Google Scholar 

  141. Nikiforov Y, Gnepp DR. Pediatric thyroid cancer after the Chernobyl disaster: Pathomorphologic study of 84 cases (1991–1992) from the Republic of Belarus. Cancer 1994; 74: 748–766.

    Article  PubMed  CAS  Google Scholar 

  142. Ain KB. Papillary thyroid carcinoma etiology, assessment, and therapy. Endocrinol Metabol Clin North Am 1995; 24: 711–760.

    CAS  Google Scholar 

  143. Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: A pooled analysis of seven studies. Radiat Res 1995; 141: 259–277.

    Article  PubMed  CAS  Google Scholar 

  144. Schneider AB, Shore Freedman E, Ryo UY, Bekerman C, Favus M, Pinsky S. Radiation-induced tumors of the head and neck following childhood irradiation. Prospective studies. Medicine (Baltimore) 1985; 64: 1–15.

    CAS  Google Scholar 

  145. Carcangiu ML, Zampi G, Rosai J. Poorly differentiated (“insular”) thyroid carcinoma. A reinterpretation of Langhans’ “wuchernde Struma”. Am J Surg Pathol 1984; 8: 655–668.

    Article  PubMed  CAS  Google Scholar 

  146. Pilotti S, Collini P, Mariani L, et al. Insular carcinoma-A distinct de novo entity among follicular carcinomas of the thyroid gland. Am J Surg Pathol 1997; 21: 1466–1473.

    Article  PubMed  CAS  Google Scholar 

  147. LiVolsi VA. Follicular lesions of the thyroid. In: LiVolsi VA, ed. Surgical Pathology of the Thyroid. W. B. Saunders, Philadelphia, PA, 1990, pp. 173–212.

    Google Scholar 

  148. Guiter GE, Auger M, Ali SZ, Allen EA, Zakowski MF. Cytopathology of insular carcinoma of the thyroid. Cancer 1999; 87: 196–202.

    Article  PubMed  CAS  Google Scholar 

  149. Burman KD, Ringel MD, Wartofsky L. Unusual types of thyroid neoplasms. Endocrinol Metabol Clin North Am 1996; 25: 49–68.

    Article  CAS  Google Scholar 

  150. van den Brekel MW, Hekkenberg RJ, Asa SL, Tomlinson G, Rosen IB, Freeman JL. Prognostic features in tall cell papillary carcinoma and insular thyroid carcinoma. Laryngoscope 1997; 107: 254–259.

    Article  PubMed  Google Scholar 

  151. Hassoun AAK, Hay ID, Goellner JR, Zimmerman D. Insular thyroid carcinoma in adolescents-A potentially lethal endocrine malignancy. Cancer 1997; 79: 1044–1048.

    Article  PubMed  CAS  Google Scholar 

  152. Sanz J, Cerpa F, Dominguez M, et al. [Insular carcinoma of the thyroid]. Rev Med Chil 1999; 127: 329–331.

    PubMed  CAS  Google Scholar 

  153. Marchesi M, Biffoni M, Biancari F, et al. Insular carcinoma of the thyroid. A report of 8 cases. Chir Ital 1998; 50: 73–75.

    PubMed  CAS  Google Scholar 

  154. Russo D, Tumino S, Arturi F, et al. Detection of an activating mutation of the thyrotropin receptor in a case of an autonomously hyperfunctioning thyroid insular carcinoma. J Clin Endocrinol Metab 1997; 82: 735–738.

    Article  PubMed  CAS  Google Scholar 

  155. Mazzaferri EL. Undifferentiated thyroid carcinoma and unusual thyroid malignancies. In: Mazzaferri EL, Samaan N, eds. Endocrine Tumors. Blackwell Scientific, Boston, MA, 1993, pp. 378–398.

    Google Scholar 

  156. Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert H, Samaan NA. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 1990; 66: 321–330.

    Article  PubMed  CAS  Google Scholar 

  157. LiVolsi VA, Brooks JJ, Arendash Durand B. Anaplastic thyroid tumors. Immunohistology. Am J Clin Pathol 1987; 87: 434–442.

    PubMed  CAS  Google Scholar 

  158. Nel CJ, van Heerden JA, Goellner JR, et al. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases. Mayo Clin Proc 1985; 60: 51–58.

    Article  PubMed  CAS  Google Scholar 

  159. Tallroth E, Wallin G, Lundell G, Lowhagen T, Einhorn J. Multimodality treatment in anaplastic giant cell thyroid carcinoma. Cancer 1987; 60: 1428–1431.

    Article  PubMed  CAS  Google Scholar 

  160. Woolner LB, Beahrs OH, Black BM, McConahey WM, Keating RF Jr. Classification and prognosis of thyroid carcinoma. Am J Surg 1961; 102: 354–387.

    Article  PubMed  CAS  Google Scholar 

  161. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418–428.

    Article  PubMed  CAS  Google Scholar 

  162. Lu WT, Lin JD, Huang HS, Chao T. Does surgery improve the survival of patients with advanced anaplastic thyroid carcinoma? Otolaryngol Head Neck Surg 1998; 118: 728–731.

    PubMed  CAS  Google Scholar 

  163. Asakawa H, Kobayashi T, Komoike Y, et al. Chemosensitivity of anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma. Anticancer Res 1997; 17: 2757–2762.

    PubMed  CAS  Google Scholar 

  164. Mitchell G, Huddart R, Harmer C. Phase II evaluation of high dose accelerated radiotherapy for ana-plastic thyroid carcinoma. Radiother Oncol 1999; 50: 33–38.

    Article  PubMed  CAS  Google Scholar 

  165. Tennvall J, Lundell G, Hallquist A, et al. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma: report on two protocols. Cancer 1994; 74: 1348–1354.

    Article  PubMed  CAS  Google Scholar 

  166. Simpson WJ. Anaplastic thyroid carcinoma: a new approach. Can J Surg 1980; 23: 25–27.

    PubMed  CAS  Google Scholar 

  167. Ahuja S, Ernst H. Chemotherapy of thyroid carcinoma. J Endocrinol Invest 1987; 10: 303–310.

    PubMed  CAS  Google Scholar 

  168. Kim JH, Leeper RD. Treatment of anaplastic giant and spindle cell carcinoma of the thyroid gland with combination Adriamycin and radiation therapy. A new approach. Cancer 1983; 52: 954–957.

    Article  PubMed  CAS  Google Scholar 

  169. Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 1987; 60: 2372–2375.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Richard T. Kloos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ernest L. Mazzaferri MD,MACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Center for Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Medical School, Chicago, IL, USA

    Mark E. Molitch MD

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kloos, R.T., Mazzaferri, E.L. (2002). Thyroid Cancer. In: Molitch, M.E. (eds) Challenging Cases in Endocrinology. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-277-7_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-277-7_6

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-249-0

  • Online ISBN: 978-1-59259-277-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation